This study is currently not recruiting participants.

Single Patient Emergency Use of Lorlatinib for Treatment of Brain Metastases from Lung Cancer with a ROS-1 Mutation

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

This is a one single patient treatment protocol using the investigational drug Lorlatinib, for a 31 year old patient with lung cancer, (ROS-1 mutation) who experienced disease progression leading to multiple brain metastases while being treated with crizotinib.

Description

This is a one single patient treatment protocol using the investigational drug Lorlatinib, for a 31 year old patient with lung cancer, (ROS-1 mutation) who experienced disease progression leading to multiple brain metastases while being treated with crizotinib.

Details
Condition lung cancer
Age 100years or below
Clinical Study IdentifierTX7058
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.